Novartis strikes $1.5B deal for UK biotech Myricx Bio
Seeking Alpha ·
Novartis ( NVS ) to acquire UK-based biotechnology company Myricx Bio, in a deal worth up to $1.5B, strengthening its oncology pipeline with a next-generation cancer drug platform. Under the terms of the agreement, Novartis ( NVS ) will pay $1.1B upfront, with an additional $400M
DYAX Investor Sentiment
Bullish (Long) 38% · Bearish (Short) 62%
390 participants
Related News
- Foxconn sees record Q2 revenue, cautions on geopolitics for Q3
- ProFrac Holding Corp. Completes Refinancing of Asset-Based Lending Facility and Enhances Financial Flexibility
- AI infrastructure firm Crusoe eyes $3bn funding round
- Kosmos Energy details H1 operations, cuts net debt by $400M
- Aliphatic Hydrocarbon Market to Hit $6.81 Billion by 2032 with 4.4% CAGR
- Apple, Nvidia supplier Unimicron aims for $1.4B in global depositary share sale